Sensitivity and specificity data submitted meets MHRA requirements
Genedrive PLC (GDR.L) CE-IVD certification for Point-of-Care Genedrive®COV19-ID kit
genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that further to the announcement of 29 November 2021, its rapid point of care Genedrive®COV19-ID Kit has received CE-IVD
Genedrive PLC (GDR.L) POC kit submitted for CE-IVD certification
Point-of-care Genedrive®COV19-ID submitted for CE-IVD certification Sets new benchmark in speed, accuracy and ease of use
Genedrive PLC (GDR.L) Audited Final Results
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces its audited Final Results for the year ended 30 June 2021.
Genedrive PLC (GDR.L) Result of Open Offer
London, UK – 29 September 2021: genedrive plc (LSE: GDR), the near-patient molecular diagnostics company, announces that it has conditionally raised total gross proceeds of approximately £1.1 million through the
Genedrive PLC (GDR.L) New Genedrive system readied for AIHL launch
New Genedrive® system readied for Antibiotic Induced Hearing Loss launch
Genedrive PLC (GDR.L) Genedrive® COVID-19 Point of Care device update
genedrive plc (AIM: GDR), the near-patient molecular diagnostics company, provides an update on the development of its Genedrive® COV19-ID Kit, a rapid Point of Care (PoC) molecular test for SARS-CoV-2
Genedrive PLC (GDR.L) COVID-19 PCR test approved by Indian regulator
Genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that the Genedrive® 96 SARS-CoV-2 Kit has been formally approved by the Indian Council of Medical Research (“ICMR”).
Genedrive PLC (GDR.L) Excellent performance data for Genedrive® HCV test
Excellent performance of Genedrive®HCV -ID Kit in large multi-centre study
Genedrive PLC (GDR.L) PHE National Framework Agreement
Genedrive successful in PHE National Framework Agreement for Diagnostics Goods and Services
Genedrive PLC (GDR.L) Half Year Report
genedrive plc (LSE: GDR), the near-patient molecular diagnostics company, announces unaudited interim results for the six months to 31 December 2020.